Equillium, Inc. (NASDAQ:EQ) has received an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $13.33.
Several brokerages have recently issued reports on EQ. SVB Leerink reduced their price objective on Equillium from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, January 5th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research report on Monday, November 15th. Stifel Nicolaus began coverage on Equillium in a research report on Friday, October 29th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Equillium in a research report on Monday, October 18th.
EQ opened at $3.67 on Wednesday. The business’s fifty day moving average is $4.65 and its two-hundred day moving average is $5.51. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.85 and a current ratio of 11.85. The company has a market cap of $107.86 million, a price-to-earnings ratio of -2.72 and a beta of 1.34. Equillium has a one year low of $3.35 and a one year high of $11.33.
In related news, CFO Jason A. Keyes sold 5,000 shares of the stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $5.08, for a total transaction of $25,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 32.70% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Victory Capital Management Inc. increased its stake in Equillium by 9.4% during the third quarter. Victory Capital Management Inc. now owns 3,170,199 shares of the company’s stock worth $21,621,000 after acquiring an additional 273,324 shares during the last quarter. Vanguard Group Inc. increased its stake in Equillium by 31.4% during the second quarter. Vanguard Group Inc. now owns 840,545 shares of the company’s stock worth $4,950,000 after acquiring an additional 200,955 shares during the last quarter. Deutsche Bank AG increased its stake in Equillium by 1.8% during the second quarter. Deutsche Bank AG now owns 356,461 shares of the company’s stock worth $2,100,000 after acquiring an additional 6,461 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Equillium during the second quarter worth about $1,285,000. Finally, Geode Capital Management LLC increased its stake in Equillium by 2.4% during the third quarter. Geode Capital Management LLC now owns 154,185 shares of the company’s stock worth $1,051,000 after acquiring an additional 3,603 shares during the last quarter. Institutional investors own 24.92% of the company’s stock.
Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.